CTLT:NYE-Catalent Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 59.41

Change

0.00 (0.00)%

Market Cap

USD 3.10B

Volume

2.57M

Analyst Target

USD 102.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent Inc is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's segments include Oral Technologies, Medication Delivery Solutions and Development & Clinical Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-10 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-2.19 (-1.24%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

-0.11 (-0.81%)

USD 45.03B
HLN Haleon plc

-0.23 (-2.42%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.23 (-1.53%)

USD 12.67B
ELAN Elanco Animal Health

-0.15 (-1.05%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.22 (-2.35%)

USD 3.44B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.05 (+0.54%)

USD 2.86B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

+0.03 (+5.96%)

USD 1.73M
EBS Emergent Biosolutions Inc

-1.08 (-9.02%)

N/A

ETFs Containing CTLT

EVNT AltShares Event-Driven ET.. 3.94 % 0.00 %

-0.03 (-0.79%)

USD 4.87M
ARB AltShares Trust - AltShar.. 2.72 % 0.00 %

+0.05 (+-0.79%)

USD 0.07B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

-0.05 (-0.79%)

USD 2.57B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-1.00 (-0.79%)

N/A
JKK 0.00 % 0.30 %

N/A

N/A
MNA IQ Merger Arbitrage ETF 0.00 % 0.76 %

+0.04 (+-0.79%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.52 (-0.79%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
USLB 0.00 % 0.35 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

+0.14 (+-0.79%)

USD 5.30B
TWOK 0.00 % 0.10 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.81 (-0.79%)

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.23% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.23% 73% C 84% B
Trailing 12 Months  
Capital Gain 77.08% 73% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.08% 73% C 89% A-
Trailing 5 Years  
Capital Gain 20.12% 79% B- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.12% 79% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 47% F 58% F
Dividend Return 6.60% 40% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.94% 40% F 19% F
Risk Adjusted Return 13.21% 53% F 31% F
Market Capitalization 3.10B 60% D- 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.10 11% 3%
Price/Book Ratio 3.04 50% 29%
Price / Cash Flow Ratio 40.24 10% 7%
Price/Free Cash Flow Ratio 38.59 10% 7%
Management Effectiveness  
Return on Equity -11.19% 60% 20%
Return on Invested Capital 1.45% 30% 32%
Return on Assets -0.18% 30% 23%
Debt to Equity Ratio 134.77% 22% 26%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector